H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review

H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

H. Lundbeck AS (Lundbeck), a subsidiary of The Lundbeck Foundation, carries out the research, development, manufacturing and marketing of pharmaceuticals for the treatment of the central nervous system (CNS) diseases including psychiatric and neurological disorders. The company's products are indicated for the treatment of diseases such as Alzheimer's disease, depression, Parkinson's disease, schizophrenia, alcohol dependence, anxiety, bipolar I disorder, epilepsy and Huntington's disease, among others. It operates production facilities in Denmark, France, Italy and China and research centers in China and Denmark. Lundbeck sells its products primarily to pharmaceutical distributors, pharmacies and hospitals in Europe, the US and other countries. Lundbeck is headquartered in Valby, Denmark.

H. Lundbeck AS Key Recent Developments

May 12,2020: H. Lundbeck: Strong momentum across all strategic brands with 35% growth in Q1 2020, financial guidance maintained
Mar 04,2020: Lundbeck receives grant from The Michael J. Fox Foundation for Parkinson’s disease research
Feb 06,2020: Strong momentum with 28% growth across all strategic brands in 2019. For 2020, Lundbeck expects revenue growth of 2-6%
Jan 15,2020: NNIT and Lundbeck extend collaboration
Nov 05,2019: H. Lundbeck: Double-digit growth for all strategic brands in 9M 2019 and FY 2019 guidance raised

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
H. Lundbeck AS - Key Facts
H. Lundbeck AS - Key Employees
H. Lundbeck AS - Key Employee Biographies
H. Lundbeck AS - Major Products and Services
H. Lundbeck AS - History
H. Lundbeck AS - Company Statement
H. Lundbeck AS - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
H. Lundbeck AS - Business Description
Product Category: Abilify Maintena
Overview
Performance
Product Category: Brintellix/Trintellix
Overview
Performance
Product Category: Cipralex/Lexapro
Overview
Performance
Product Category: Effects from Hedging
Performance
Product Category: Northera
Overview
Performance
Product Category: Onfi
Overview
Performance
Product Category: Other pharmaceuticals
Performance
Product Category: Other Revenue
Performance
Product Category: Rexulti
Overview
Performance
Product Category: Sabril
Overview
Performance
Geographical Segment: Europe
Target Markets
Performance
Geographical Segment: International Markets
Target Markets
Performance
Geographical Segment: North America
Performance
R&D Overview
H. Lundbeck AS - Corporate Strategy
H. Lundbeck AS - SWOT Analysis
SWOT Analysis - Overview
H. Lundbeck AS - Strengths
H. Lundbeck AS - Weaknesses
H. Lundbeck AS - Opportunities
H. Lundbeck AS - Threats
H. Lundbeck AS - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
H. Lundbeck AS, Recent Deals Summary
Section 5 – Company’s Recent Developments
May 12, 2020: H. Lundbeck: Strong momentum across all strategic brands with 35% growth in Q1 2020, financial guidance maintained
Mar 04, 2020: Lundbeck receives grant from The Michael J. Fox Foundation for Parkinson’s disease research
Feb 06, 2020: Strong momentum with 28% growth across all strategic brands in 2019. For 2020, Lundbeck expects revenue growth of 2-6%
Jan 15, 2020: NNIT and Lundbeck extend collaboration
Nov 05, 2019: H. Lundbeck: Double-digit growth for all strategic brands in 9M 2019 and FY 2019 guidance raised
Nov 05, 2019: Double-digit growth for all strategic brands in 9M 2019 and FY 2019 guidance raised
Sep 17, 2019: Lundbeck signs $1.95bn deal to buy Alder BioPharmaceuticals
Aug 14, 2019: Double-Lundbeck’s digit growth for all strategic brands and DKK 8.5 billion in revenue and DKK 2.3 billion in EBIT
Aug 14, 2019: Lundbeck appoints new EVP, People & Communication
May 30, 2019: Hyphens Pharma signs exclusive distribution agreement with Lundbeck for Vietnam
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook